Clinical and morphological peculiarities of brca1-associated breast cancer in young women

Close metadata

Recommended articles:

Complications after one-stage and two-stage breast reconstruction depending on the method of reconstruction and risk factors. Plastic Surgery and Aesthetic Medicine. 2024;(2):16-21

Perforator fasciocutaneous flaps in resections for breast cancer. Plastic Surgery and Aesthetic Medicine. 2024;(2):81-86

The impact of artificial intelligence on double reading of mammograms. Russian Journal of Preventive Medicine. 2024;(5):32-37

Reconstructive plastic surgery in combined treatment of breast cancer: predictive risk factors of complications and reconstruction failure. P.A. Herzen Journal of Oncology. 2024;(3):13-19

Targeted lymphadenectomy with sentinel lymph node biopsy in patients with breast cancer cT1-3N1M0 after neoadjuvant polychemotherapy. P.A. Herzen Journal of Oncology. 2024;(3):73-78

Breast cancer: types of implantable materials for replacement of postresection defects. P.A. Herzen Journal of Oncology. 2024;(3):85-89

Intrathecal chemotherapy for leptomeningeal metastases in patients with breast cancer. Burdenko's Journal of Neurosurgery. 2024;(3):31-37

Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer. Russian Journal of Archive of Pathology. 2024;(4):23-30

Indocyanine green is an integral part of breast reconstructive surgery using perforator flaps. Pirogov Russian Journal of Surgery. 2024;(8):34-40

Leading trends in breast cancer incidence in the Republic of Crimea. P.A. Herzen Journal of Oncology. 2024;(4):42-47

Young patients with breast cancer and BRCA1 gene mutation is of certain scientific interest. Differences in molecular pathogenesis between BRCA-associated and sporadic breast cancer can predetermine clinical and morphological features of both groups.

Keywords:

breast cancer

reproductive age

BRCA1/

Authors:

Avtomonov D.E.

NII klinicheskoĭ onkologii FGBU "RONTs im. N.N. Blokhina" RAMN, Moskva

Parokonnaia A.A.

Rossiĭskiĭ nauchnyĭ onkologicheskiĭ tsentr im. N.N. Blokhina RAMN

Lyubchenko L.N.

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Nechushkin M.I.

Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina RAMN, Moskva

Nurberdyev M.B.

NII klinicheskoĭ onkologii FGBU "RONTs im. N.N. Blokhina" RAMN, Moskva

List of references:

Ford D., Easton D., Bishop D. et al. Consortium BCL. Risk of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692-695.
Couch F.J. et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336: 1409-1415.
Gar'kavtseva R.F., Kazubskaya T.P., Lyubchenko L.N. i dr. Nasledstvennyi rak: identifikatsiya, geneticheskaya geterogennost', mediko-geneticheskoe konsul'tirovanie. M: Vestn RAMN 2001; 9: 27-32.
Davydov M.I., Letyagin V.P. Seminar po klinicheskoi mammologii. M 2006; 104.
Hampl M., Plaschke J., Burgemeister R. et al. Sequence analysis of BRCA1 gene in young breast cancer patients and or positive family history. Langenbecks Arch Chir Kongressbd 1998; 115: 1: Suppl: 267-272.
Johnson S.M., Shaw J.A., Walker R.A. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 2002; 10: 98: 2: 205-209.
Robson M., Gilewski T., Haas B. et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998; 16: 5: 1642-1649.
Ford D., Easton D., Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
Fedorova O.E., Lyubchenko L.N., Payanidi Yu.G., Kazubskaya T.P., Amosenko F.A., Gar'kavtseva R.F., Zasedatelev A.S., Nasedkina T.V. Ispol'zovanie biochipov pri izuchenii rasprostranennykh mutatsii v genakh BRCA1/2 i CHEK 2 u bol'nykh organospetsifichnym rakom yaichnikov i pervichno-mnozhestvennymi zlokachestvennymi novoobrazovaniyami s porazheniem yaichnikov (rossiiskaya populyatsiya). Mol biol 2007; 41: 1: 37-42.
Lyubchenko L.N. Genodiagnostika nasledstvennoi predraspolozhennosti k raku molochnoi zhelezy i razrabotka sistemy individual'nogo prognozirovaniya razvitiya, techeniya i profilaktiki zabolevaniya: Avtoref. dis. ... kand. med. nauk. M 2002; 41.
Lyubchenko L.N., Gar'kavtseva R.F. DNK-dagnostika i mediko-geneticheskoe konsul'tirovanie pri nasledstvennom rake molochnoi zhelezy. V kn.: Rak molochnoi zhelezy. Pod red. N.E. Kushlinskogo, S.M. Portnogo, K.P. Laktionova. M: RAMN 2005; 198-209.
Johannson O., Ranstam J., Borg A. et at. Sunital of BRCA 1 breast and ovarian cancer in patients: apopulation-based studyfrom southem Suleden. J Clin Oncol 1998; 16: 1: 397-404.
Rebbeck T., Friebel T., Lynch H. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 6: 1055-1062.
Graeser M., Christoph E. et al. Risk of contralateral Breast cancer in BRCA1 and BRCA2 mutants. J Clin Oncol 2009; 27: 35: 25-30.
Van der Groep P., Bouter A., van der Zanden R. et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 2006; 59: 611-617.
Loman N., Johannson O., Bendahl P. et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998; 83: 310-319.
Noguchi S., Kasugai T., Miki Y. et al. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999; 85: 2200-2205.
Karp S.E., Tonin P.N., Begin L.R. et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997; 80: 3: 435-441.
Johannsson O.T., Idvall I., Anderson C. et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362-371.
Kim S., Rimm D., Carter D. et al. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer. Breast 2003; 9: 167-174.
Atchley Deann P. et al. Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer. J Clin Oncol 2008; 2: 4: 312-318.
Musolino A., Bella M.A., Bortesi B. et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. Breast 2007; 16: 280-292.
Wen-Feng Li, Zhen Hu, Nan-Yan Rao et al. The prevalence of BRCA1 and BRCA2 germline mutations in highrisk breast cancer patients of Chinese Han nationality: Two recurrent mutations were identified. Breast Cancer Res Treat 2008; 110: 1: 99-109.
Byrski T., Gronwald J., Huzarski T. et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008; 108: 289-296.
Haffty B.G., Yang Q., Reiss M. et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 36: 5652-5657.
Foulkes W.D., Stefansson I.M., Chappuis P.O. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-1485.
Foulkes W.D., Brunet J.S., Stefansson I.M. et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascularproliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64: 830-835.
Robson M., Rajan P., Rosen P., Gilewski T., Hirschaut Y., Pressman P., Haas B., Norton L., Offit K. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998; 58: 9: 1839-1842.
Johannson O., Bendahl O. et al. Steroid receptors in hereditary breast carcinomas associated with BRCA 1 or BRCA 2 mutations or unknoun susceptibilit genes. Cancer 1998; 83: 310-319.
Verhoog L.C., Brekelmans C.T.M. et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 9099: 316-321.
Marcus J., Watson P., Page D. et al. Hereditmy breast cancerpathobiologi, prognosis, and BRCA l and BRCA 2 gene linkage. Cancer 1996; 77: 697-709.
Marcus J., Watson P., Page D. et al. BRCA2 bereditary breast cancer phenotype. Breast Cancer Res Treat 1997; 44: 275-277.
Stoppa-Lyonnet D., Ansquer Y., Dreyfus H. et al. Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol 2000; 18: 4053-4059.
Hoogerbrugge N., Bult P., Bonenkamp J., Ligtenberg M., Kiemeney L., Niermeijer M., Brunner H. Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer 2006; 42: 15: 2492-2498.
Claus E., Petruzclla S., Matloff E., Carter D. Prevalence of BRCAl and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005; 293: 8: 964-969.
Mote P.A., Leary J.A., Avery K.A., Sandelin K., Kirk J.A., Clarke C.L. Germline mutations in BRCAl or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosom Cancer 2004; 39: 3: 236-248.
Cavalli L.R., Singh B., Isaacs C., Dickson R.B., Haddad B.R. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Genet Cytogenet 2004; 149: l: 38-43.
Lynch H.T., Lynch J., Narod S., Fitzgibbons R. Jr. Hereditary breast cancer and family cancer syndromes. World J Surg 1994; 18: l: 21-31.
Lalle P., De Latour M., Rio P., Bignon Y.J. Detection of allelic losses on 17ql2-q21 chromosomal region in benign lesions and malignant tumors occurring in a familial context. Oncogene 1994; 9: 2: 437-442.
Dupont W., Page D. Risk fastors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
Turner N.C., Reis-Filho J.S. Basal-like breastcancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-5853.
Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
Laakso M., Loman N., Borg A. et al. Cytokeratin 5/14-positive breast cancer: True basal phenotype confined to BRCA1 tumors. Mod Pathol 2005; 18: 1321-1328.
Palacios J., Honrado E., Osorio A. et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: Differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003; 9: 3606-3614.

Close metadata